Table of Contents
Chapter - 1
- INTRODUCTION
- 1.1. The State of Stem Cell Science and Technology
- Types of Stem Cells
- Stem Cell R&D
- 1.2. Stem Cells in Normal Development
- From Fertilized Ovum to Multicellular Organism
- Defining Characteristics of Stem Cells
- 1.3. From Stem Cell Science to Technology
- Early Thoughts on Reprogramming and Cloning
- The Origin of Embryonic Stem (ES) Cells
- The State of Stemness
- “PluriNet,” the Regulatory Network behind Pluripotency
- Epigenetics and MicroRNAs
- Induced Pluripotent Stem (iPS) Cells
- The Future: hES or iPS Cells?
- Medical Tourism: Protecting Healthcare Consumers
Chapter - 2
- THE TECHNOLOGICAL LANDSCAPE
- 2.1. Adult (Tissue-Specific) Stem Cells
- Reproductive Structures and Prenatal Tissues
- Postnatal Tissues
- Hematopoietic Stem Cells (HSCs)
- Mesenchymal Stem Cells (MSCs)
- Perivascular Stem Cells (“Pericytes”)
- Neural Stem and Progenitor Cells
- 2.2. Tools and Technologies in Context
- Culturing ES Cells
- Characterizing ES Cells
- Maintaining or Differentiating ES Cells
- Umbilical Cord Stem Cells to Treat Bronchopulmonary Dysplasia
- 2.3. Tissue Engineering
- Different Tissues, Different Challenges
- Cells + ECM
- Hydrogels
- 2.4. Supplies and Services
- The Care and Feeding of Stem Cells: Media, Markers, and Matrix
- Cells for Sale (or Free)
Chapter - 3
- APPLICATIONS
- 3.1. Drug Discovery and Development
- Identifying New - and Not So New - Drug Targets
- Targeting the Pre-manifest Stage of Disease
- Revealing Disease Subtypes
- Toxicology
- 3.2. Stem Cells to Recapitulate Disease
- 3.3. Therapeutics
- 3.4. A Trio of Therapeutics
- The Failing Heart
- Cancer Stem Cells
- The Eye
Chapter - 4
- COMMERCIAL OUTLOOK
- 4.1. Funding
- Pharma Comes on Board
- Venture Capital
- 4.2. Regulatory Hurdles
- 4.3. Marketing Concerns
- 4.4. Intellectual Property
- Human ES Cells: The WARF Patents
- Adult Stem Cells: Patenting Neurospheres
- iPS Cells: Donor Sources
- 4.5. Public Perception of Stem Cell Technology
- 4.6. Hype and False Hope Breed Medical Tourism
- 4.7. Bioethical Concerns
- Medical Tourism Revisited
- Protecting Cell Donors
- Stem Cell Banks
- 4.8. A Policy Patchwork
- Global Policy
- The United States: A Closer Look
Chapter - 5
- EXPERT INTERVIEWS
- 5.1. Expert Roundtable 1: Induced Pluripotent (iPS) Cells
- Participants: George Daley, MD, PhD, past president of ISSCR and
associate in medicine at Children' s Hospital Boston; Shinya Yamanaka, MD,
PhD, senior investigator, Gladstone Institute of Cardiovascular Disease and
the L.K. Whittier Foundation Investigator in stem cell biology and professor
of anatomy at the University of California, San Francisco and director,
Center for iPS Cell Research and Application and professor, Institute for
Frontier Medical Sciences, Kyoto University, Japan; Kathrin Plath, PhD,
assistant professor at UCLA; Rudolf Jaenisch, MD, member of the Whitehead
Institute and a professor of biology at MIT (Cambridge, MA); Junying Yu,
PhD, assistant scientist in James Thomson' s lab at the University of
Wisconsin in Madison; Sir Ian Wilmut, PhD, director of the Centre for
Regenerative Medicine at the Queen' s Medical Research Institute, University
of Edinburgh.
- 5.2. Expert Roundtable 2: Stem Cells - From Bench to Bedside
- Participants: Katherine A. High, MD, professor of pediatrics at the
University of Pennsylvania School of Medicine and director of the Center for
Cellular and Molecular Therapeutics at The Children' s Hospital of
Philadelphia; Giulio Cossu, MD, director of the Stem Cell Research
Institute, San Raffaele Scientific Institute, Milan; Judy Lieberman, MD,
PhD, senior investigator at the Immune Disease Institute, professor of
pediatrics, and director, division of AIDS, all at Harvard Medical School;
Alok Srivastava, MD, head of the department of hematology at Christian
Medical College (Vellore, India).
- 5.3. Interview with Dennis Steindler, PhD
- Executive Director, the Evelyn F. and William L. McKnight Brain
Institute, University of Florida in Gainesville
- 5.4. Interview with Sally Temple, PhD
- Scientific Director, the New York Neural Stem Cell Institute
- Professor, Albany Medical College and the University at Albany
- 5.5. Interview with Amy Wagers, PhD
- Investigator, Joslin Diabetes Center
- Assistant Professor of Pathology, Harvard Medical School
Chapter - 6
- SELECTED COMPANY PROFILES
- 6.1. Cellartis
- 6.2. Cryo-Cell
- 6.3. Geron
- 6.4. Novocell
- 6.5. Osiris Therapeutics
- 6.6. PrimeGen Biotech
- 6.7. Stem Cell Sciences
- 6.8. StemCells
- 6.9. Vet-Stem Regenerative Veterinary Medicine
References
Glossary of Selected Terms
Company Index with Web Addresses
|
Related Report
|
View Cart
